Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.

Berkelmans GFN, Gudbjörnsdottir S, Visseren FLJ, Wild SH, Franzen S, Chalmers J, Davis BR, Poulter NR, Spijkerman AM, Woodward M, Pressel SL, Gupta AK, van der Schouw YT, Svensson AM, van der Graaf Y, Read SH, Eliasson B, Dorresteijn JAN.

Eur Heart J. 2019 Jan 9. doi: 10.1093/eurheartj/ehy839. [Epub ahead of print]

PMID:
30629157
2.

Development of a cardiovascular diseases risk prediction model and tools for Chinese patients with type 2 diabetes mellitus: A population-based retrospective cohort study.

Wan EYF, Fong DYT, Fung CSC, Yu EYT, Chin WY, Chan AKC, Lam CLK.

Diabetes Obes Metab. 2018 Feb;20(2):309-318. doi: 10.1111/dom.13066. Epub 2017 Aug 25.

PMID:
28722290
4.

Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.

Basu S, Sussman JB, Rigdon J, Steimle L, Denton BT, Hayward RA.

PLoS Med. 2017 Oct 17;14(10):e1002410. doi: 10.1371/journal.pmed.1002410. eCollection 2017 Oct.

5.

Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.

Kaasenbrood L, Poulter NR, Sever PS, Colhoun HM, Livingstone SJ, Boekholdt SM, Pressel SL, Davis BR, van der Graaf Y, Visseren FL; CARDS, ALLHAT, and ASCOT Investigators.

Circ Cardiovasc Qual Outcomes. 2016 May;9(3):213-21. doi: 10.1161/CIRCOUTCOMES.115.001980. Epub 2016 May 11.

6.

Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: The Steno Type 1 Risk Engine.

Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, Jørgensen ME.

Circulation. 2016 Mar 15;133(11):1058-66. doi: 10.1161/CIRCULATIONAHA.115.018844. Epub 2016 Feb 17.

PMID:
26888765
8.

Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study.

Ferket BS, van Kempen BJ, Heeringa J, Spronk S, Fleischmann KE, Nijhuis RL, Hofman A, Steyerberg EW, Hunink MG.

PLoS Med. 2012;9(12):e1001361. doi: 10.1371/journal.pmed.1001361. Epub 2012 Dec 27.

9.

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.

Hemmingsen B, Gimenez-Perez G, Mauricio D, Roqué I Figuls M, Metzendorf MI, Richter B.

Cochrane Database Syst Rev. 2017 Dec 4;12:CD003054. doi: 10.1002/14651858.CD003054.pub4. Review.

PMID:
29205264
10.

Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model.

Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D'Agostino RB Sr, Massaro JM, van der Graaf Y, Cramer MJM, Kappelle LJ, de Borst GJ, Steg PG, Visseren FLJ.

J Am Heart Assoc. 2018 Aug 21;7(16):e009217. doi: 10.1161/JAHA.118.009217.

11.
12.

Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries.

Uthman OA, Hartley L, Rees K, Taylor F, Ebrahim S, Clarke A.

Cochrane Database Syst Rev. 2015 Aug 4;(8):CD011163. doi: 10.1002/14651858.CD011163.pub2. Review.

13.

Global cardiovascular mortality risk in the adult Polish population: prospective assessment of the cohorts studied in multicentre national WOBASZ and WOBASZ Senior studies.

Piotrowski W, Waśkiewicz A, Cicha-Mikołajczyk A.

Kardiol Pol. 2016;74(3):262-73. doi: 10.5603/KP.a2015.0175. Epub 2015 Sep 14.

14.

Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: A Systematic Evidence Report for the U.S. Preventive Services Task Force [Internet].

Lin JS, Evans CV, Johnson E, Redmond N, Burda BU, Coppola EL, Smith N.

Rockville, MD: Agency for Healthcare Research and Quality (US); 2018 Jul.

15.

Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.

Moelands SV, Lucassen PL, Akkermans RP, De Grauw WJ, Van de Laar FA.

Cochrane Database Syst Rev. 2018 Dec 28;12:CD005061. doi: 10.1002/14651858.CD005061.pub3.

PMID:
30592787
16.

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.

Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH.

Cardiovasc Diabetol. 2018 Aug 24;17(1):118. doi: 10.1186/s12933-018-0759-z.

18.

Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep.

19.
20.

Fixed-dose combination therapy for the prevention of cardiovascular disease.

de Cates AN, Farr MR, Wright N, Jarvis MC, Rees K, Ebrahim S, Huffman MD.

Cochrane Database Syst Rev. 2014 Apr 16;(4):CD009868. doi: 10.1002/14651858.CD009868.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Mar 06;3:CD009868.

Supplemental Content

Support Center